SB 220025

Overview

SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor ( IC 50 = 60 nM). SB 220025 also inhibits p56 Lck and PKC with IC 50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > p38 MAPK | Products > Signaling Pathways > Src | Products > Signaling Pathways > PKC

Product Information

• Catalog No.: HY-112291
• CAS No.: 165806-53-1
• Molecular Formula: C18H19FN6
• Molecular Weight: 338.38
• Purity: 99.90%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source